FDA to expedite review of Pharmacyclics-Janssen's blood cancer drug

08/29/2013 | Manufacturing.net · American City Business Journals

Pharmacyclics obtained priority-review status from the FDA for its application to market ibrutinib as a treatment for previously treated mantle cell lymphoma and chronic lymphocytic leukemia. The application's acceptance triggers payment of a $75 million fee from partner Janssen Biotech.

View Full Article in:

Manufacturing.net · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC